<code id='21DF4352FB'></code><style id='21DF4352FB'></style>
      • <acronym id='21DF4352FB'></acronym>
      <center id='21DF4352FB'><center id='21DF4352FB'><tfoot id='21DF4352FB'></tfoot></center><abbr id='21DF4352FB'><dir id='21DF4352FB'><tfoot id='21DF4352FB'></tfoot><noframes id='21DF4352FB'>
      • <optgroup id='21DF4352FB'><strike id='21DF4352FB'><sup id='21DF4352FB'></sup></strike><code id='21DF4352FB'></code></optgroup>
        5. <b id='21DF4352FB'><label id='21DF4352FB'><select id='21DF4352FB'><dt id='21DF4352FB'><span id='21DF4352FB'></span></dt></select></label></b><u id='21DF4352FB'></u>
          <i id='21DF4352FB'><strike id='21DF4352FB'><tt id='21DF4352FB'><pre id='21DF4352FB'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-30 23:16:47 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：2647
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Young boy dies in trial for Pfizer Duchenne gene therapy
                                
                            
          Next article：  
                                      
                                          As demand for Covid shots wanes, Moderna seeks its next success
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles